Online inquiry

IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2676MR)

This product GTTS-WQ2676MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Low bone mineral density research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2676MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10981MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ11166MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ13203MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ12243MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ11240MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ3606MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ7131MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ7217MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW